Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 1—January 2017

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010

Xizhong Cui1, Leisha D. Nolen1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine A. Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. EichackerComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (X. Cui, J. Sun, P.Q. Eichacker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.D. Nolen, C.P. Quinn, A.E. Boyer, K. Hendricks, S. Shadomy, W.A. Bower); Glasgow Royal Infirmary, Glasgow, UK (M. Booth, L. Donaldson); James Paget University Hospital, Norfolk, UK (P. Bothma); Royal Derby Hospital, Derby, UK (O. Judd); Crosshouse Hospital, Kilmarnock, UK (P. McConnell)

Main Article

Table 6

Treatment after hospital admission and durations of ICU and hospital stay in survivors and nonsurvivors who did and did not receive AIG-IV, Scotland, UK, 2009–2010*

Treatment characteristic AIG-IV nonrecipient AIG-IV recipient p value
Treatments after hospital admission
Days to AIG-IV receipt, median (IQR) NA 1 (1–3), n = 15 NA
ICU care 35.7 (10/28) 86.7 (13/15) 0.001
Receipt of antimicrobial drugs 100 (28/28) 100 (15/15) 1.00
No. antimicrobial drugs/patient during hospital stay, mean ± SE‡ 3.0 ± 0.2, n = 28 5.3 ± 0.2, n = 15 <0.0001
Surgery on day of admission 17.9 (5/28) 73.3 (11/15) 0.0003
Surgery during hospital stay 39.3 (11/28) 93.3 (14/15) 0.0006
Days to surgery, median (IQR) 1 (0–2), n = 11 0 (0–0.33), n = 14 0.24
Vasopressors 13.3 (2/15) 33.3 (4/12) 0.36
Mechanical ventilation
33.3 (5/15)
50 (7/14)
Duration of ICU and hospital stay, median (IQR)
Survivors’ ICU stay, d 0, n = 22 4.5 (0.9–19.0), n = 10 0.0008
Nonsurvivors’ time to death, d 1.3 (0.6–2.0), n = 6 4.0 (3.0–5.0), n = 5 0.07
Survivors’ hospital stay, d 9.5 (2.0–17), n = 22 38 (31–42), n = 10 0.001

*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate no. patients for whom data were available. Bold indicates significant differences between AIG-IV recipients and nonrecipients. AIG-IV, anthrax immune globulin intravenous; ICU, intensive care unit; IQR, interquartile range; NA, not applicable.

Main Article

1These authors contributed equally to this article.

Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.